Literature DB >> 30941459

[Motivational interviewing : A possibility for doctor-patient communication in schizophrenia?]

Jens Reimer1,2,3, Jens Kuhn4,5, Rita Wietfeld6, Wolfgang Janetzky7, Karolina Leopold8.   

Abstract

Motivational interviewing (MI) has become established nowadays as an approach for a cooperative style of conversation to promote intrinsic motivation for change by exploring and resolving ambivalences. The change of addictive behavior is no longer sought by exerting pressure or lecturing/converting attempts of convincing or persuasion but by activating existing but "buried" or newly acquired self-motivation to change. The MI is now also used to change the treatment of other health-related behavior and chronic diseases, including schizophrenic disorders. Compared to the efficacy of MI in the addiction area, the data situation in schizophrenic patients is still insufficient. According to the available studies, MI can positively influence important aspects of disease-related impairments, such as medication adherence, the frequency and severity of psychotic relapses, the duration of hospitalization, the level of function, insight into the disease and cognitive rehabilitation. The practical implementation of MI requires a good knowledge of the method as well as changes in treatment principles and work processes.

Entities:  

Keywords:  Communication strategy; Doctor-patient communication; Medication adherence; Motivational Interviewing; Schizophrenia

Mesh:

Year:  2019        PMID: 30941459     DOI: 10.1007/s00115-019-0702-x

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  31 in total

Review 1.  Motivational interviewing: a systematic review and meta-analysis.

Authors:  Sune Rubak; Annelli Sandbaek; Torsten Lauritzen; Bo Christensen
Journal:  Br J Gen Pract       Date:  2005-04       Impact factor: 5.386

2.  Shared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango).

Authors:  C Charles; A Gafni; T Whelan
Journal:  Soc Sci Med       Date:  1997-03       Impact factor: 4.634

3.  World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects.

Authors:  Alkomiet Hasan; Peter Falkai; Thomas Wobrock; Jeffrey Lieberman; Birte Glenthoj; Wagner F Gattaz; Florence Thibaut; Hans-Jürgen Möller
Journal:  World J Biol Psychiatry       Date:  2012-12-06       Impact factor: 4.132

4.  The effect of motivational interviewing on medication adherence and hospitalization rates in nonadherent patients with multi-episode schizophrenia.

Authors:  Emile Barkhof; Carin J Meijer; Leo M J de Sonneville; Don H Linszen; Lieuwe de Haan
Journal:  Schizophr Bull       Date:  2013-09-26       Impact factor: 9.306

5.  [The "ideal" doctor from the view of psychiatric patients].

Authors:  Susanne Theisel; Tanja Schielein; Hermann Spiessl
Journal:  Psychiatr Prax       Date:  2010-06-15

6.  The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009.

Authors:  Julie Kreyenbuhl; Robert W Buchanan; Faith B Dickerson; Lisa B Dixon
Journal:  Schizophr Bull       Date:  2009-12-02       Impact factor: 9.306

Review 7.  Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review.

Authors:  Robert B Zipursky; Natasja M Menezes; David L Streiner
Journal:  Schizophr Res       Date:  2013-08-21       Impact factor: 4.939

8.  Integrated motivational interviewing and cognitive behavioural therapy for people with psychosis and comorbid substance misuse: randomised controlled trial.

Authors:  Christine Barrowclough; Gillian Haddock; Til Wykes; Ruth Beardmore; Patricia Conrod; Tom Craig; Linda Davies; Graham Dunn; Emily Eisner; Shôn Lewis; Jan Moring; Craig Steel; Nicholas Tarrier
Journal:  BMJ       Date:  2010-11-24

9.  Effects of motivational interviewing-based adherence therapy for schizophrenia spectrum disorders: a randomized controlled trial.

Authors:  Wai Tong Chien; Jolene H C Mui; Eric F C Cheung; Richard Gray
Journal:  Trials       Date:  2015-06-14       Impact factor: 2.279

10.  Medication adherence in patients with schizophrenia: a qualitative study of the patient process in motivational interviewing.

Authors:  Jos Dobber; Corine Latour; Lieuwe de Haan; Wilma Scholte Op Reimer; Ron Peters; Emile Barkhof; Berno van Meijel
Journal:  BMC Psychiatry       Date:  2018-05-18       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.